Skip to main content
. 2021 Jun 2;9(8):892–902. doi: 10.1002/ueg2.12109

TABLE 4.

Univariate and multivariate analysis

Highly suggestive cACLD (n = 141) Absence of cACLD (n = 11299) p Multivariate analysis
Age (Y) 58 (9.6) 50.3 (12.5) <0.001 OR 1.04 (1.02–1.06; p = 0.001)
Gender (M:F) 113:28 (80.1:19.9) 4692:6561 (41.7:58.3) 0.002
BMI (kg/m2) 29.1 (5.7) 26.7 (4.7) <0.001
Waist circumference (cm) 100.5 (16.6) 90.3 (13.5) <0.001
Systolic/diastolic blood pressure (mmHg) 137.0 (16.6)/80.5 (10) 130.1 (16.8)/77.8 (9.8) <0.001
Liver test
ALT (IU/L) 39.8 (37.9) 24.2 (16.9) <0.001 OR 1.02 (1.01–1.03; p < 0.001) OR 1.005 (1.003–1.007; p < 0.001)
AST (IU/L) 39.9 (30.9) 24.2 (12.2) <0.001
GGT (IU/L) 102.0 (127.1) 30.7 (48.8) <0.001
Alkaline phosphatase (IU/L) 87.3 (38.3) 71.7 (28.5) <0.001
Bilirubin (mg/dl) 1.5 (0.6) 1.4 (17.7) 0.7
Abnormal transaminases (AST or ALT > 40 IU/L) 54 (38.3) 1059 (9.4) <0.001
Healthy transaminase cutoffs (ALT <30 male or <19 female) 103 (73) 5863 (51.9) <0.001
Albumin (g/dl) 4.4 (0.4) 4.5 (0.3) 0.01
Glucose (mg/dl) 103.8 (47.3) 91.4 (28.8) <0.001
Platelets (x103) 219.7 (83.4) 247 (61.6) <0.001 OR 0.993 (0.989–0.997; p < 0.001)
HDL cholesterol (mg/dl) 57.4 (17.5) 58.8 (16.1) <0.001
Triglycerides (mg/dl) 169.8 (113.2) 140.8 (98.1) <0.001
Metabolic syndrome (NCEP ATP III) 36 (25.5) 1729 (15.3) <0.001 OR 2.1 (1.4–3.3; p = 0.001)
HCV Ab+ 2 (1.4) 141 (1.2) 0.9
HBsAg+ 0 (0) 90 (0.8) 0.3
Harmful use of alcohol 28 (19.9) 1021 (9.0) <0.001 OR 1.8 (1.05–3.1; p = 0.03)

Note: Highly suggestive cACLD (LSM > 15 kPa) vs. absence of cACLD. Quantitative data are expressed as mean (standard deviation). Qualitative data are expressed as number and percentage. Variables included in the multivariate analysis: age, gender, ALT, AST, GGT, alkaline phosphatase, platelets, metabolic syndrome, alcohol consumption.